Fasting Without the Hunger: Mimio Health's Clinically-Backed Pill

SAN FRANCISCO, CA – March 02, 2026 – A San Francisco-based nutritechnology company is making a bold claim: the metabolic and cellular benefits of a 36-hour fast can now be achieved through a daily supplement, no dietary changes required. Mimio Health today announced the publication of a breakthrough clinical trial in the prestigious journal Nature Scientific Reports, providing what it calls the first-of-its-kind evidence for its fasting mimetic formulation.

The study found that the supplement, named Mimio™, delivered significant fasting-like advantages, including improved cardiometabolic health, better appetite regulation, and reduced cellular stress compared to a placebo. The findings could represent a significant shift in the burgeoning longevity and wellness markets, where the benefits of fasting are widely praised but the practice itself remains a challenge for many.

The Science of 'Fasting in a Pill'

At the heart of Mimio Health's innovation is a concept called "biomimetics"—the science of decoding and recreating the body's own biological processes. The company’s journey began not by inventing new molecules, but by meticulously mapping the molecular changes that occur in the human body during a prolonged 36-hour fast. This research, led by co-founders with deep expertise in nutritional biochemistry from UC Davis, identified a specific set of human bioactives that become highly elevated when the body enters a fasted, regenerative state.

The resulting formulation is a patented blend of four key ingredients: spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide (OEA). While these names may be unfamiliar to most, they are not foreign to the body. They are naturally occurring compounds involved in cellular renewal (spermidine), energy metabolism (nicotinamide), and appetite signaling (PEA and OEA). By combining them, Mimio aims to activate the same beneficial cellular pathways as fasting, effectively tricking the body into a regenerative state without the discomfort and difficulty of food deprivation.

"These findings demonstrate, in a gold-standard placebo-controlled trial, that Mimio's fasting mimetic formulation can deliver similar metabolic, cellular, and appetite-regulating benefits as fasting – without fasting," said Dr. Chris Rhodes, PhD, CEO and Co-Founder of Mimio Health, in a statement. "We observed significant improvements in cholesterol and glucose metabolism, oxidative stress, digestion, and hunger control that mimicked our previous findings of the benefits of a 36-hour fast, without requiring participants to change how they eat or live."

Gold-Standard Study Raises Bar for Supplements

In the often-criticized, multi-billion dollar supplement industry, where bold claims frequently lack rigorous scientific backing, Mimio Health's approach stands out. The company invested in a randomized, double-blind, placebo-controlled clinical trial—the gold standard for scientific evidence—to validate its product.

The eight-week study, conducted in partnership with the decentralized clinical research organization People Science, enrolled 42 healthy adults with an average age of 62 who had elevated BMI and HbA1c, putting them at higher risk for cardiometabolic issues. The results were statistically significant and compelling:
* Cardiometabolic Health: Participants taking Mimio saw significant reductions in total cholesterol, LDL ("bad") cholesterol, LDL particle number, and non-HDL cholesterol. They also experienced a drop in fasting glucose levels.
* Appetite Regulation: A remarkable 91% of individuals in the Mimio group reported improved control over their appetite. This included reduced daily hunger, less mental distraction from cravings (often termed "food noise"), and improved feelings of satiety after meals.
* Digestive Comfort: The formulation was found to be well-tolerated and also led to a significant reduction in reports of bloating and digestive discomfort compared to the placebo group.

The study's modern design, utilizing the Chloe app platform for decentralized data collection, allowed for efficient and scalable research, a model that could become more common for consumer health innovators seeking to validate their products with scientific rigor.

Tapping into a Multi-Billion Dollar Wellness Market

Mimio Health's breakthrough enters a market ripe for innovation. The global longevity ingredients market was valued at over $900 million in 2024 and is projected to double by 2034, while the weight loss supplement industry is a titan, valued at over $31 billion in 2023. Mimio's product sits at the intersection of these booming sectors.

The individual ingredients in its formulation are already part of this growth. Spermidine, linked to cellular renewal, and PEA, known for its anti-inflammatory properties, represent rapidly growing supplement markets on their own. However, Mimio's competitive edge lies in its patented, synergistic blend and, crucially, the high-level clinical validation to back its specific "fasting mimetic" claim. This differentiates it from both single-ingredient supplements and food-based programs like the Fasting-Mimicking Diet, offering a more convenient, evidence-backed alternative.

With $2.5 million in seed funding secured in 2023 from Better Ventures, the company is positioned to challenge a crowded field. Its focus on human-centric research and "gold-standard" evidence could set a new benchmark for credibility in a market where consumers are increasingly skeptical of unsubstantiated claims.

The Road Ahead: From Lab to Longevity

While the eight-week study results are promising, the road ahead involves answering questions about long-term use. The trial demonstrated excellent short-term safety and tolerability, but further research will be needed to confirm these effects over months or years of daily supplementation. For a product aimed at longevity and healthspan extension, long-term data will be paramount for widespread acceptance among medical professionals and discerning consumers.

From a regulatory standpoint, the publication in Nature Scientific Reports provides powerful substantiation for the company's health claims, a critical requirement from the Federal Trade Commission (FTC), which polices advertising. Making "structure/function" claims like "supports cardiometabolic health" is standard for supplements, but having such robust, peer-reviewed evidence is not.

This study is just the first step in Mimio Health's ambitious vision. The company is already applying its biomimetic research framework to decode and replicate the health benefits of other regenerative states, including exercise, deep sleep, and meditation. The goal is to build a suite of products that can provide the body's own healing mechanisms on-demand, potentially redefining the future of proactive, personalized health and extending not just lifespan, but healthspan—the number of healthy, vibrant years of life.